IVX has the licence from Cho to develop the treatment in ANZ.
It is no different to any other biotech which has bought a licence from any underlying entity who controls the IP and then funds the trials to develop the drug in certain jurisdictions.
So a) I don’t necessarily agree with your assertion that IVX should control the IP and b) as I said with my previous post, the company has materially expanded its addressable market through this deal, so there is a value equation to it.
Imo Cho’s path to extracting material commercial value from Photosoft is solely through IVX anyway, so I am not overly concerned at this point in time
IVX Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)